Efranat Pharma
Anticancer Immunotherapy Treatment
Company Overview
Snapshot
Founded in December 2009 by Avi Levin and Boaz Shoham, Efranat Pharma operates with 11–50 employees. The company has raised $4.5 million across one funding round from 5 investors. In November 2014, Efranat Pharma raised $4.5 million.
Business overview
Efranat Pharma is a Health Tech & Life Sciences company focused on developing anticancer immunotherapy treatments. The company's core technology is based on engineering a natural vitamin D binding protein into a potent immune modulator to fight cancer and chronic viral diseases. Its primary product, EF-022, is an immunomodulator designed to activate macrophages, which are white blood cells crucial for the immune system's defense against cancer. Efranat Pharma serves the biopharmaceutical and healthcare industries, targeting patients with advanced solid tumors.
Strategic signal
In June 2017, Efranat Pharma initiated a Phase 1 clinical trial for its EF-022 immunomodulator in human cancer patients with advanced solid tumors at the Sheba Medical Center. This development signaled the company's progression from preclinical studies to human trials, validating its therapeutic approach and indicating a critical step towards potential market entry for its anticancer immunotherapy.
Log in to access full profile ›Company Intelligence Q&A
- What is Efranat Pharma's primary focus?
- Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule, aiming to engage the body's own immune system against cancer.
- When was Efranat Pharma founded?
- Efranat Pharma was founded in December 2009.
- What is EF-022?
- EF-022 is Efranat Pharma's primary product, an immunomodulator engineered from a natural vitamin D binding protein that activates macrophages to fight cancer and chronic viral diseases.
- What was a significant funding event for Efranat Pharma?
- In November 2014, Efranat Pharma raised $4.5 million from investors including.
- What clinical trials has Efranat Pharma conducted?
- In June 2017, Efranat Pharma initiated a Phase 1 clinical trial for EF-022 in human cancer patients with advanced solid tumors at the Sheba Medical Center.